The treatment of tumor-bearing mice, with either targeted therapies such as osimertinib for EGFR-mutant tumors or immunotherapies such as anti-PD-1 for KRAS-driven tumors, results in variable degrees of tumor shrinkage, with some tumors showing a strong response and other tumors showing a minimal response. This evidence concerns the gene KRAS and neoplasm.